Passage Bio Terminates Gemma Collaboration and Philadelphia Office Lease
Passage Bio gave written notice on May 21, 2026 to end its research, collaboration and license agreement with Gemma Biotherapeutics, and on May 22, 2026 agreed with its landlord to terminate its 37,000-square-foot office lease at 2005 Market Street. The company agreed to pay a $2.3 million lease termination fee, and the Gemma termination takes effect under the agreement's terms. For shareholders, the filing shows the company is ending a partnership and reducing its office footprint, though the filing does not describe the financial effect beyond the fee.
Key points
- Gemma Collaboration Agreement, dated July 31, 2024, terminated by written notice on May 21, 2026
- Gemma had conducted preclinical and IND-enabling work for the Huntington's disease program and a paused Temporal Lobe Epilepsy program
- Lease termination agreement signed May 22, 2026 with Commerce Square Partners; $2.3 million termination fee
- Leased space was about 37,000 square feet, with a lease originally set to expire in December 2031; substantially all of it was subleased in 2023
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 27, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.